Not everyone with ductal carcinoma in situ of the breast treated with breast preservation needs post-excisional radiation therapy

Breast

Volumn 9, Issue 4, 2000, Pages 189-193

  Silverstein, M J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAMOXIFEN;

ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST OF ILLNESS; FIBROSIS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NECROSIS; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TIME;

EID: 0033830553     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.1997.0127     Document Type: Article

References (26)

1. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer
2. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: Intraductal Carcinoma (Ductal Carcinoma In Situ)
3. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from national surgical adjuvant breast and bowel project B-17
4. Radiotherapy in breast conserving treatment for ductal carcinoma in situ: First results of EORTC randomized phase III trial 10853
5. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: Intraductal Carcinoma
6. Tamoxifen in treatment of intraductal breast cancer: National surgical adjuvant breast and bowel project B-24 randomized controlled trial
7. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
8. Tamoxifen after surgery/RT decreases local recurrence risk in DCIS patients
9. Radiation therapy for in situ or localized breast cancer
10. Pathologic analysis of the NSABP-B17 trial
11. The influence of margin width on local control in patients with ductal carcinoma in situ (DCIS) of the breast
12. Predicting local recurrence in patient with ductal carcinoma in situ
13. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence
14. Prognostic classification of breast ductal carcinoma in situ
15. A prognostic index for ductal carcinoma in situ of the breast
16. Mammographically-detected ductal carcinoma in situ of the breast analysed with a new classification. A study of 127 cases: Correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins and proliferative activity
17. Prognostic factors and local recurrence in patient with ductal carcinoma in situ of the breast
18. Predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-analysis
19. Developing a prognostic index for ductal carcinoma in situ of the breast: Are we there yet?
20. Predictors of local recurrence following excision alone for ductal carcinoma in situ
21. Whole organ studies
22. Three dimensional imaging of mammary ductal carcinoma is situ: Clinical implications
23. Side effects of radiation therapy
24. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast
25. Favourable and unfavorable effects on long-term survival of radiotherapy for early breast cancer
26. Radiotherapy for early breast cancer: Was a comprehensive overview of trials needed?